Opportunity Information: Apply for PAR 16 338
Apply for PAR 16 338
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.395,.
- This funding opportunity was created on Jun 16, 2016 and posted on Jun 16, 2016.
- Applicants must submit their applications by Jul 05, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) (PAR 16-338) is a National Institutes of Health (NIH) grant opportunity focused on improving adolescent HPV vaccination by studying one of the most influential drivers of vaccination behavior: the healthcare provider's recommendation. The central idea behind the announcement is that a recommendation alone is not always enough; the surrounding healthcare delivery system can strengthen, weaken, or even block the impact of what a provider says. The FOA supports research that explains when and why provider recommendations lead to actual HPV vaccine initiation and completion among adolescents, and what can be changed in real-world care settings to increase uptake.
The opportunity emphasizes that HPV vaccine decisions are shaped by factors at multiple levels. On the provider side, characteristics such as communication style, confidence in discussing HPV vaccination, competing clinical priorities, time constraints, and beliefs about parental acceptance can influence whether a recommendation is made and how strongly it is delivered. On the parent and patient side, factors like vaccine knowledge, perceived risk, trust in clinicians, cultural beliefs, concerns about safety, and readiness to vaccinate can determine whether a recommendation is accepted. The FOA also highlights the clinical setting as a major influence, including practice workflow, reminder and recall systems, electronic health record prompts, standing orders, staffing patterns, clinic policies, and broader organizational or health system supports that affect whether vaccination is offered, administered, and followed up.
Because the topic sits at the intersection of prevention science and healthcare operations, the FOA calls for multidisciplinary research capacity. Projects are expected to draw on expertise in cancer prevention (given HPV's role in multiple cancers), behavioral science across both adult and adolescent decision-making, immunization promotion strategies, and healthcare delivery research. In practice, this means studies may examine communication approaches, system-level interventions, or implementation strategies that help translate strong recommendations into completed vaccination, especially in settings where missed opportunities are common.
This is an R01 research grant mechanism under the U.S. Department of Health and Human Services, National Institutes of Health (listed here as HHS-NIH11). The funding activity category is Education and Health, and it is associated with CFDA numbers 93.393 and 93.395. The FOA was posted and created on June 16, 2016, with a listed closing date of July 5, 2019. The source data provided does not specify an award ceiling or the expected number of awards.
Eligibility is broad and includes many types of domestic organizations and government entities, reflecting the expectation that relevant research can be led by universities, health systems, public health partners, and other research-capable institutions. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; non-federally recognized tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education where specified); for-profit organizations other than small businesses; small businesses; and other entities as further clarified in the full eligibility text.
Overall, the FOA is aimed at generating actionable evidence about how to optimize the conditions under which provider recommendations translate into real vaccination behavior. Rather than treating low HPV vaccine uptake as only a knowledge or attitude problem, it encourages research that accounts for workflow, systems, and the practical realities of clinical care, with the goal of informing interventions and policies that measurably increase adolescent HPV vaccination.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01) and is identified as PAR 16-338.
Which federal agency is offering this funding opportunity?
This is a National Institutes of Health (NIH) funding opportunity under the U.S. Department of Health and Human Services (listed as HHS-NIH11).
What is the main purpose of PAR 16-338?
The purpose is to improve adolescent HPV vaccination by researching how and when a healthcare provider's recommendation leads to actual HPV vaccine initiation and completion, and what can be changed in real-world healthcare settings to increase uptake.
Why does this FOA focus on provider recommendations?
The FOA is based on the idea that a provider recommendation is one of the most influential drivers of vaccination behavior, but a recommendation alone may not be enough. The surrounding healthcare delivery system can strengthen, weaken, or block the effect of what the provider says.
What outcomes is the research expected to address?
Studies supported by this FOA are expected to explain when and why provider recommendations translate into HPV vaccine initiation and completion among adolescents, and identify changes in care settings that measurably increase vaccination uptake.
What types of factors does the FOA say influence HPV vaccine decisions?
The FOA emphasizes multi-level influences, including:
- Provider factors (for example communication style, confidence, time constraints, competing priorities, beliefs about parental acceptance)
- Parent and patient factors (for example knowledge, perceived risk, trust, cultural beliefs, safety concerns, readiness to vaccinate)
- Clinical setting and system factors (for example workflow, reminder/recall systems, EHR prompts, standing orders, staffing patterns, clinic policies, organizational or health system supports)
What provider-related issues may be studied under this FOA?
The FOA highlights provider characteristics and constraints that can shape whether a recommendation is made and how strongly it is delivered, including communication approach, confidence discussing HPV vaccination, competing clinical priorities, time limitations, and beliefs about parental acceptance.
What parent or patient-related issues may be studied under this FOA?
The FOA notes that acceptance of a recommendation can depend on factors such as vaccine knowledge, perceived risk, trust in clinicians, cultural beliefs, concerns about safety, and readiness to vaccinate.
What healthcare delivery or clinic system issues may be studied under this FOA?
The FOA identifies clinical setting factors that can influence whether vaccination is offered, administered, and followed up, including workflow design, reminder/recall systems, electronic health record prompts, standing orders, staffing patterns, clinic policies, and broader organizational or health system supports.
Does the FOA support research beyond education or attitudes?
Yes. The FOA explicitly encourages research that does not treat low HPV uptake only as a knowledge or attitude problem, but instead accounts for workflow, systems, and practical realities of clinical care.
What kinds of research approaches does the FOA suggest?
Based on the description provided, the FOA supports studies that may examine communication approaches, system-level interventions, or implementation strategies that help translate strong recommendations into completed vaccination, especially in settings where missed opportunities are common.
Why does the FOA emphasize multidisciplinary research capacity?
The topic is described as sitting at the intersection of prevention science and healthcare operations. Projects are expected to draw on expertise in cancer prevention, behavioral science across adult and adolescent decision-making, immunization promotion strategies, and healthcare delivery research.
What grant mechanism is used for this opportunity?
This opportunity uses the R01 research project grant mechanism.
What is the funding activity category listed for this opportunity?
The funding activity category is listed as Education and Health.
What CFDA numbers are associated with this FOA?
The opportunity is associated with CFDA numbers 93.393 and 93.395.
When was this FOA posted, and what is the closing date shown?
The FOA was posted and created on June 16, 2016, and the listed closing date is July 5, 2019.
Does the provided information include an award ceiling or the expected number of awards?
No. The source data provided does not specify an award ceiling or the expected number of awards.
Who is eligible to apply for this grant opportunity?
Eligibility is broad and includes many domestic organizations and government entities. The list provided includes:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Non-federally recognized tribal organizations
- Public housing authorities/Indian housing authorities
- Nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education where specified)
- For-profit organizations other than small businesses
- Small businesses
- Other entities as further clarified in the full eligibility text
Is this opportunity intended only for universities?
No. While universities are eligible, the eligibility description also includes multiple levels of government, tribal entities, health-system-relevant organizations, nonprofits, and for-profit entities, reflecting that relevant research may be led by a range of research-capable institutions.
What is the broader goal of funding research under this FOA?
The FOA aims to generate actionable evidence on how to optimize the conditions under which provider recommendations translate into real vaccination behavior, with the intent to inform interventions and policies that increase adolescent HPV vaccination.
Does the FOA connect HPV vaccination to cancer prevention?
Yes. The FOA notes that projects are expected to draw on expertise in cancer prevention, given HPV's role in multiple cancers.
What does the FOA mean by missed opportunities?
The provided description references settings where missed opportunities are common and suggests studying interventions or strategies that help ensure that strong recommendations result in vaccination being administered and completed. The source text does not provide a separate formal definition beyond that context.
Is the research expected to address both starting and finishing the HPV vaccine series?
Yes. The FOA explicitly mentions vaccine initiation and completion as key outcomes.
Browse more opportunities from the same category: Education, Health
Next opportunity: Magnetic Miniaturized and Monolithically-Integrated Components (M3IC)
Previous opportunity: Legal Education Visiting Scholar Program for Afghanistan
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 338
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 338) also looked into and applied for these:
| Funding Opportunity |
|---|
| U.S.-Russia Bilateral Collaborative Research Partnerships (CRP) on the Prevention and Treatment of HIV/AIDS and HIV-Associated Comorbidities (R01) Apply for RFA AA 17 006 Funding Number: RFA AA 17 006 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Cancer Target Discovery and Development Network (U01) Apply for RFA CA 16 014 Funding Number: RFA CA 16 014 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer (R21) Apply for RFA CA 16 015 Funding Number: RFA CA 16 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $100,000 |
| Limited Competition: The Chernobyl Tissue Bank - Coordinating Center (U24) Apply for RFA CA 16 502 Funding Number: RFA CA 16 502 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Coordinating Center for Population-based Research to Optimize Cancer Screening (PROSPR) (U24) Apply for RFA CA 16 017 Funding Number: RFA CA 16 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
| Research Centers for Population-based Research to Optimize Cancer Screening (PROSPR) Initiative (UM1) Apply for RFA CA 16 016 Funding Number: RFA CA 16 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| FY 2017 American Schools and Hospitals Abroad (ASHA) Program (Request for Comments) Apply for APS ASHA 17 000001 Funding Number: APS ASHA 17 000001 Agency: Agency for International Development Category: Education, Health Funding Amount: $2,000,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 17 013 Funding Number: RFA CA 17 013 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) Apply for RFA CA 17 012 Funding Number: RFA CA 17 012 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 17 011 Funding Number: RFA CA 17 011 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24) Apply for RFA CA 17 004 Funding Number: RFA CA 17 004 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $650,000 |
| PDX Development and Trial Centers (PDTCs) (U54) Apply for RFA CA 17 003 Funding Number: RFA CA 17 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $800,000 |
| Mechanisms of Cancer Drug Resistance and Sensitivity (U54) Apply for RFA CA 17 009 Funding Number: RFA CA 17 009 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) Apply for RFA CA 17 015 Funding Number: RFA CA 17 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) Apply for RFA CA 17 016 Funding Number: RFA CA 17 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) Apply for RFA CA 17 002 Funding Number: RFA CA 17 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Canine Immunotherapy Trials and Correlative Studies (U01) Apply for RFA CA 17 001 Funding Number: RFA CA 17 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) Apply for PA 17 138 Funding Number: PA 17 138 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $135,000 |
| Data Management and Coordinating Center (DMCC) for the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Collaborative Research Centers (CRC) (U24) Apply for RFA NS 17 022 Funding Number: RFA NS 17 022 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3) Apply for RFA DA 18 003 Funding Number: RFA DA 18 003 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 338", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.